SCHEMBL26807616

SCHEMBL26807616

CNC(=O)c1ccc(Oc2cc(C3CCCCC3(C)C)nc(NS(=O)(=O)c3cnn(C)c3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.36
▸ MET P08581 1/20 0.35
▸ AURKA O14965 3/20 0.34
▸ AURKB Q96GD4 3/20 0.34
▸ FGFR1 P11362 4/20 0.34
▸ KDR P35968 4/20 0.34
▸ FGFR2 P21802 3/20 0.34
▸ FGFR4 P22455 3/20 0.34
▸ FGFR3 P22607 3/20 0.34
▸ FLT3 P36888 2/20 0.34
▸ EGFR P00533 1/20 0.34
▸ AXL P30530 1/20 0.34
▸ TYRO3 Q06418 1/20 0.34
▸ MERTK Q12866 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ JAK1 P23458 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CRHBP P24387 1/20 0.32
▸ CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26807615 0.92 F2 (0.37) HRH3METFGFR1KDRFGFR2
SCHEMBL26810538 0.90 EGFR (0.36) HRH3METAURKAAURKBFGFR1
SCHEMBL26807618 0.90 HRH3 (0.39) HRH3METFGFR1KDRFGFR2
SCHEMBL26807481 0.88 HTR1A (0.39) FGFR1KDREGFRJAK1NLRP3
SCHEMBL26807632 0.88 HRH3 (0.40) HRH3METAURKAAURKBFGFR1
SCHEMBL26807631 0.87 HRH3 (0.39) HRH3METAURKAAURKBFGFR1
SCHEMBL26810504 0.83 MET (0.37) HRH3METAURKAAURKBFGFR1
SCHEMBL26807620 0.83 HTR1A (0.35) FGFR1KDREGFR
SCHEMBL26810534 0.82 F10 (0.40) METFGFR1KDRFGFR3EGFR
SCHEMBL26807611 0.81 CDK2 (0.34) IRAK4JAK1NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HRH3 4413/4885MET 657/4885AURKA 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback